drugset / Trial / NCT01875523
PK of Serelaxin in Severe Renal Impairment and ESRD
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The study is designed to evaluate the pharmacokinetics, safety and tolerability, immunogenicity and pharmacogenetics of a single dose of serelaxin/RLX030 in patients with severe renal impairment and end-stage-renal-disease (ESRD) compared to healthy volunteers.
Timeline
- Start
- 2013-08
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serelaxin | Protein / enzyme biologic | — | Intravenous |